Bosentan (As Monohydrate)
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Bosentan (As Monohydrate) |
| DrugBank ID | DB00559 |
| Brand Names (EU) | Stayveer |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.96% |
Approved Indication (EMA)
Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with World Health Organization (WHO) functional class III. Efficacy has been shown in: primary (idiopathic and familial) PAH; PAH secondary to scleroderma without significant interstitial pulmonary disease; PAH associated with congenital systemic-to-pulmonary shunts and Eisenmenger’s physiology. Some improvements have also been shown in patients with PAH WHO functional class II. Stayveer is
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | scleroderma (disease) | 99.96% | DL |
| 2 | rheumatoid arthritis | 99.80% | DL |
| 3 | brachydactyly-syndactyly syndrome | 99.74% | DL |
| 4 | limited systemic sclerosis | 99.65% | DL |
| 5 | colobomatous microphthalmia-rhizomelic dysplasia syndrome | 99.62% | DL |
| 6 | localized scleroderma | 99.54% | DL |
| 7 | pulmonary hypertension | 99.50% | DL |
| 8 | pseudoxanthoma elasticum, forme fruste | 99.45% | DL |
| 9 | kyphoscoliotic heart disease | 99.43% | DL |
| 10 | elastoma | 99.35% | DL |
| 11 | systemic sclerosis | 99.28% | DL |
| 12 | gout | 99.21% | DL |
| 13 | hypertrichosis (disease) | 99.04% | DL |
| 14 | Ambras type hypertrichosis universalis congenita | 98.93% | DL |
| 15 | uterine polyp | 98.84% | DL |
| 16 | malformation syndrome with odontal and/or periodontal component | 98.81% | DL |
| 17 | epulis | 98.81% | DL |
| 18 | syndrome with a Dandy-Walker malformation as major feature | 98.77% | DL |
| 19 | diffuse cutaneous systemic sclerosis | 98.77% | DL |
| 20 | polyp of vocal cord | 98.77% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.